Clinical trials: Metastatic Gastrointestinal Cancer
Neoplasm Metastasis, Liver Neoplasms
Study of Safety and Tolerability of Intravenous CRS-100 in Adults With Carcinoma and Liver Metastases
This clinical trial evaluated the safety and tolerability of CRS-100, an investigational agent containing a live-attenuated strain of Listeria monocytogenes (Lm).
- Conditions
- Neoplasm Metastasis, Liver Neoplasms, Carcinoma
- Trial name
- NCT00327652
- Testing
- CRS-100
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Anza Therapeutics, Inc.
Non Small Cell Lung Cancer, Colorectal Cancer
A Study of YL202 in Patients With Advanced Solid Tumors
This study is a multicenter, open-label, phase II study of YL202 in China to evaluate the efficacy, safety, and PK characteristics of YL202 in selected patients with advanced solid tumors.
- Conditions
- Non Small Cell Lung Cancer, Colorectal Cancer, Cervical Cancer, Locally Advanced or Metastatic Solid Tumors
- Trial name
- NCT07202364
- Testing
- YL202
- Where
- China
- Volunteers
- 100 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Metastatic Colorectal Cancer
Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux® (Merck) in Metastatic Colorectal Cancer
The study is designed as phase III, randomized, two armed, parallel, double blind (patient and assessor blinded), active controlled, and equivalency clinical trial with primary endpoint of Progression-Free Survival of Cetuximab®…
- Trial name
- NCT03391934
- Testing
- Cetuximab + FOLFIRI
- Where
- Iran
- Volunteers
- 234 people
- Sponsor
- Cinnagen
Metastatic Colorectal Cancer
PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer
This was a phase Ib study of PDR001 in combination with bevacizumab and mFOLFOX6 as first line therapy in patients with metastatic microsatellite stable (MSS) colorectal cancer.
- Trial name
- NCT03176264
- Testing
- PDR001, bevacizumab, mFOLFOX6
- Where
- United Kingdom
- Volunteers
- 1 people
- Sponsor
- Novartis Pharmaceuticals
Colorectal Cancer, Colorectal Carcinoma
A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
This study will assess the safety of RAD001 when given together with cetuximab and irinotecan
- Conditions
- Colorectal Cancer, Colorectal Carcinoma, Colorectal Tumors, Neoplasms, Colorectal
- Trial name
- NCT00478634
- Testing
- RAD001, Cetuximab, Irinotecan
- Where
- 16 sites in United States
- Volunteers
- 19 people
- Sponsor
- Novartis Pharmaceuticals
Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC)
A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors
This clinical trial is evaluating a drug called MDSY-2140 in participants with hematologic malignancies and advanced solid tumors.
- Conditions
- Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC), Gastric Cancer Adenocarcinoma Metastatic, Ovarian Cancer Metastatic
- Trial name
- NCT07899632
- Testing
- MDSY-1240
- Volunteers
- 75 people
- Sponsor
- Medsyn Biopharma, LLC
Metastatic Pancreatic Cancer, NSCLC, Metastatic
Patient Reported Outcomes Registry in Patient With Cancer Cachexia
Evaluation of patient reported outcomes (PRO) with tumor cachexia in a real life setting.
- Trial name
- PROXie (NCT02983500)
- Where
- Germany
- Volunteers
- 253 people
- Sponsor
- iOMEDICO AG
Thyroid Cancer, Colon Cancer
QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer
This is a phase 1b/2 study to evaluate the safety, tolerability, and efficacy of ETBX-011 vaccine used in combination with ALT-803 in subjects with locally advanced or metastatic CEA-expressing cancers whose tumor has recurred…
- Conditions
- Thyroid Cancer, Colon Cancer, Ovarian Cancer, Breast Cancer
- Trial name
- NCT03127098
- Testing
- ETBX-011, ALT-803
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- NantCell, Inc.
Metastatic Uveal Melanoma, Cutaneous Melanoma
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including…
- Conditions
- Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer, Other Solid Tumors
- Trial name
- NCT03947385
- Testing
- IDE196, Binimetinib, Crizotinib
- Where
- 15 sites in United States, Australia and 1 more
- Volunteers
- 336 people
- Sponsor
- IDEAYA Biosciences
Advanced/Metastatic Solid Tumors, Colorectal Cancer
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC.
- Conditions
- Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer
- Trial name
- NCT03526835
- Testing
- MCLA-158, MCLA-158 + Pembrolizumab, MCLA-158 + FOLFIRI
- Where
- 54 sites in United States, Belgium and 5 more
- Volunteers
- 560 people
- Sponsor
- Genmab
Metastatic Colorectal Cancer
Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer
The purpose of this study is to determine if Cediranib when added to chemotherapy is more effective than chemotherapy alone in prolonging life expectancy and slowing disease progression in patients with previously untreated…
- Trial name
- HORIZON II (NCT00399035)
- Testing
- Cediranib, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin), XELOX (Capecitabine and Oxaliplatin)
- Where
- 90 sites in Argentina, Australia and 13 more
- Volunteers
- 1,254 people
- Sponsor
- AstraZeneca
Pancreatic Cancer
Talimogene Laherparepvec in Patients With Unresectable Pancreatic Cancer
The purpose of the study is to assess the safety of injections of talimogene laherparepvec into patients with pancreatic cancer that cannot be removed by surgery.
- Trial name
- NCT00402025
- Testing
- Talimogene Laherparepvec
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- BioVex Limited
Advanced Cancer, Gastric Cancer
Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer
This Phase I/Ib study is a Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GZ17-6.02 Monotherapy and in Combination with Capecitabine, Given Orally on a Daily Schedule in Patients…
- Conditions
- Advanced Cancer, Gastric Cancer, Breast Cancer, Pancreatic Cancer
- Trial name
- GEN602 (NCT03775525)
- Testing
- GZ17-6.02, Capecitabine
- Where
- 4 sites in United States
- Volunteers
- 127 people
- Sponsor
- Genzada Pharmaceuticals USA, Inc.
Non-hematologic Malignancies, Metastatic Melanoma
A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients
This Phase I clinical trial is studying the side effects and best dose of ABT-888 when given together with Temozolomide (chemotherapy) in treating patients with solid tumors, including metastatic melanoma (MM), BRCA deficient…
- Conditions
- Non-hematologic Malignancies, Metastatic Melanoma, Breast Cancer, Ovarian Cancer
- Trial name
- NCT00526617
- Testing
- ABT-888, Temozolomide
- Volunteers
- 41 people
- Sponsor
- AbbVie
Pancreas Cancer
Safety and Efficacy of the Therapeutic Vaccine GI-4000 in Combination With Gemcitabine Versus Placebo for the Treatment of Non-metastatic, Post-resection Pancreas Cancer
The GI-4000 therapeutic vaccine or placebo will be injected under the skin of post-resection, non-metastatic pancreas cancer patients.
- Trial name
- NCT00300950
- Testing
- GI-4000, Gemcitabine
- Where
- 28 sites in United States, India
- Volunteers
- 176 people
- Sponsor
- GlobeImmune
Metastatic Colorectal Cancer
A Study of Fruquintinib in Adults With Metastatic Colorectal Cancer in Poland
Metastatic colorectal cancer or mCRC is a cancer that starts in the parts of the large intestine (the colon or rectum) and has already spread to other parts of the body.
- Trial name
- NCT07623174
- Testing
- No intervention
- Where
- 10 sites in Poland
- Volunteers
- 110 people
- Sponsor
- Takeda
Unresectable/Metastatic Colorectal Cancer
EMB-01 in Combination With Chemotherapy for Unresectable or Metastatic Colorectal Cancer
This is an open-label, multicenter, Phase Ib trial designed to evaluate the safety, tolerability, and preliminary efficacy of EMB-01 in combination with chemotherapy in patients with unresectable or metastatic colorectal cancer…
- Trial name
- NCT07649655
- Testing
- EMB-01, Irinotecan, TAS-102
- Where
- 2 sites in China
- Volunteers
- 120 people
- Sponsor
- Shanghai EpimAb Biotherapeutics Co., Ltd.
Advanced Solid Tumor, Advanced/Metastatic Colorectal Cancer
Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of Simmitecan Monotherapy and Combination in Patients With Advanced Solid Tumors
This study evaluates the safety, tolerability, preliminary efficacy and pharmacokinetics of Simmitecan in patients with advanced solid tumors and Simmitecan, 5-fluorouracil and Leucovorin Calcium,thalidomide in patients with…
- Trial name
- NCT02870036
- Testing
- Simmitecan, 5-fluorouracil and Leucovorin Calcium, Thalidomide
- Where
- 9 sites in China
- Volunteers
- 243 people
- Sponsor
- Haihe Biopharma Co., Ltd.
Hepatocellular Carcinoma
Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Hepatocellular Carcinoma (HCC)
The main objective of the trial is to document the progression free survival (PFS) in advanced or metastatic hepatocellular carcinoma patients treated with NGR-hTNF as single agent.
- Trial name
- NCT00484211
- Testing
- NGR-hTNF
- Where
- 3 sites in Italy
- Volunteers
- 40 people
- Sponsor
- AGC Biologics S.p.A.
Metastatic Colorectal Cancer (mCRC)
DHF-20-1839-2: Clinical Performance Study Protocol for Therascreen® KRAS RGQ PCR Kit
To utilize the therascreen KRAS RGQ PCR Kit, as a screening test in Amgen's Phase 3 Clinical Study Protocol 20210081, in order to identify patients with mCRC KRAS G12C mutation positive tumors to be enrolled in the drug clinical…
- Trial name
- NCT06645236
- Testing
- therascreen® KRAS RGQ PCR Kit
- Where
- United Kingdom
- Volunteers
- 600 people
- Sponsor
- QIAGEN Gaithersburg, Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.